anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention provides a genetically-modified T cell comprising in its genome a modified human T cell receptor alpha gene. The modified T cell receptor alpha gene comprises an exogenous sequence of interest inserted into an intron within the T cell receptor alpha gene that is positioned 5&#39; upstream of TRAC exon 1. The exogenous sequence of interest can comprise an exogenous splice acceptor site and/or a poly A signal, which disrupts expression of the T cell receptor alpha subunit. The sequence of interest can also include a coding sequence for a polypeptide, such as a chimeric antigen receptor. Additionally, the endogenous splice donor site and the endogenous splice acceptor site flanking the intron are unmodified and/or remain functional. The invention further provides compositions and methods for producing the genetically-modified cell, and populations of the cell, and methods for the treatment of a disease, such as cancer, using such cells.
PURPOSE:To obtain a composition effective for suppressing the elevation of blood pressure by using a caseinoglycopeptide as an active component. CONSTITUTION:Caseinoglycopeptide (abbreviated to &#39;CGP&#39;) which is a glycopeptide existing in cheese whey, whey protein, whey mineral, etc., is used as an active component. In the case of using CGP as an agent for suppressing the elevation of blood pressure, it is preferably administered by peroral administration at a daily dose of 1-10g for adult. CGP can be administered by adding to a food such as cake, ice cream, yogurt and sport drink or to a feed for livestock or pet. Since CGP is originated from whey which as a useful food raw material, it has extremely high safety. The effect is further promoted by using CGP in combination with potassium.
NEW MATERIAL:The physiologically active substance M5032 of formula or its salt. USE:It has activity to inhibit enzymatic activity of cycloadenosine 3&#39;,5&#39;- monophosphate phosphodiesterase produced by microorganisms belonging to genus Sporormiella and is expected to be useful as a remedy for cardiovascular diseases, antiasthmatic agent, smooth muscle relaxant, anti-inflammatory agent, remedy for cancer, etc. It is administered to human, domestic animal, domestic fowl, etc., by oral, rectal or parenteral administration or by opthalmic instillation, etc. PREPARATION:The compound of formula or its salt is produced by culturing Sporormiella sp. M5032 strain (FERM P-9506) belonging to genus Sporormiella and capable of producing the physiologically active substance M5032 of formula in a liquid medium under a condition for the culture of fungi, e.g. under shaking or aeration and agitation and separating microbial cells containing the physiologically active substance M5032 from the cultured product by filtration or centrifugal separation.
The respiration-stimulating activity of the deproteinated blood preparation obtained according to Specification 824,375 is increased by incubating the preparation, in aqueous medium, with human protein. Incubation is performed at 35 to 40 DEG C. for at least 10 and at most 40 minutes, until the dry solids content of the preparation increases from 10-60 mgs./ml. to 40-100 mgs./ml. As human protein, blood preparations such as albumen, serum, haemolysed blood, g -globulin, or preferably Cohn&#39;s blood serum fraction IV, may be used. Animal proteins are also disclosed as providing similar enhancement of the activity of the original preparation.  Human proteins are suitably employed in proportions by weight of 3 to 5 parts per one part of the preparation, or even proportions of up to 50:1, based on the weight of the original dry solids content.  The product may be filled into ampoules and sterilised, or lyophilised.
One aspect of the invention relates to complexes of technetium (Tc) and rhenium (Re) with various heteroaromatic ligands, e.g., quinolinyl and isoquinolinyl ligands, and their use in fluoresence and radioimaging for a variety of clinical diagnostic applications, as well as radiopharmaceuticals for therapeutic applications. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium and rhenium complexes are also described. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention. ® KIPO &amp; WIPO 2007
A method and system in a first embodiment that allows authorized individuals access into controlled access locations and the ability to grant temporary and limited access to guests into these locations. The method and system allow for navigational services to be provided to members and guests, and real-time tracking and confirmation to members and administrators that guests have arrived at their destination and did not enter any unauthorized areas. The method preferably can work through a system of wireless radio, sound and/or light-based beacons communicating with member and guest&#39;s electronic devices. Members and administrators can send one or more temporary electronic access keys to a guest&#39;s smartphone or other electronic device. Wireless radio, sound and/or light-based beacons provide an access control and location tracking system with real-time data about the member and guest whereabouts, allowing for the confirmation and tracking. A system and method in a second embodiment for identifying a customer&#39;s location within a facility or place of business, such as, but not limited to a casino. The system and method provide notification to company representatives upon arrival of the customer at the given location. Additionally, the method and system allow for navigational services to be provided to customers, and real-time location determination, location tracking and confirmation to customers of location and rewards program status. The disclosed method and system can work through a system of wireless radio, sound and/or light-based beacons communicating with the customer&#39;s smartphone, computer system, or other electronic device.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an oil-in-water type emulsified composition having high ultraviolet protecting effects, excellent dispersion stability and good usability.  &lt;P&gt;SOLUTION: This oil-in-water type emulsified composition is characterized as comprising a benzotriazole derivative represented by formula (I) in an aqueous phase, one or two or more kinds of hydrophilic surfactants each having ≥10 value of HLB and titanium oxide subjected to a hydrophobization treatment in an oily phase. In the composition, the amount of the formulated titanium oxide subjected to the hydrophobization treatment is preferably 3-12 mass% based on the whole composition. In the composition, the amount of the formulated benzotriazole derivative represented by formula (I) is preferably 2-8 mass% based on the whole composition. In the composition, octyl methoxycinnamate is preferably further contained in the oily phase.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Streptomyces avermitilis lacking branched-chain 2-oxo acid dehydrogenase activity and avermectin B O-methyltransferase activity is claimed. The strain is deposited as ATCC53692. The nonnatural avermectins produced by the strain are characteised by the presence of OH gps. at the C-5 position of the aglycone moiety and/or the C-3&#39; and/or C-3&#34; positions of the oleandrose. moieties. The obtd. cpds. are useful for the same purposes as known avermectins. They are highly active antiparasitic agents having partic. utility as anthelmintics, ectoparasiticides, insecticides and acaricides.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a root canal disinfectant that sufficiently disinfects a root canal to the interior, improves disinfection capacity by making it possible to carry out disinfection for many hours and alleviates a physical burden to a patient.  &lt;P&gt;SOLUTION: The root canal disinfectant 6 for dental use is mixed with a photocatalyst (e.g. titanium dioxide 7) and a luminous material 8 in which the luminous material 8 is used for activating the photocatalyst (titanium dioxide 7). Namely, the photocatalyst (e.g. titanium dioxide 7) injected into a root canal is activated based on a light from the luminous material 8.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain an oral composition excellent in germicidal activities, and good in palatability by formulating a prescribed amount of a specific germicidal enhancer with a system comprising a quarternary ammonium salt-based germicidal agent and/or a nonionic germicidal agent. SOLUTION: This oral composition is obtained by formulating a germicidal agent containing at least one or more kinds selected from a quarternary ammonium salt-based germicidal agent and/or a nonionic germicidal agent with &gt;=0.005 wt.% cineole based on the whole amount of the composition and a nonionic surfactant. The formulating amount of the germicidal agent is 0.001-0.5 wt.% based on the whole amount of the composition. The nonionic surfactant is exemplified by a fatty acid ester of polyoxyethylenesorbitan having 5-20 mol. average polymerization degree of ethylene oxide, and 12-18 alkyl chain length of the fatty acid, and preferably formulated so as to be 0.01-5 wt.% in the whole amount of the composition. The cineole is exemplified by mint, citrus and grape, and preferably formulated so as to be 0.005-1.0 wt.%.
Disclosed are a culture medium composition for expanding and maintaining the self-renewal ability and differentiation potential of hematopoietic stem cells (HSCs), a cell population and use thereof. The culture medium composition comprises a hematopoietic stem cell medium and small molecule inhibitors of PDGFR target. The applicant has demonstrated for the first time that the PDGFR inhibitors can significantly expand HSCs during culture in vitro, while maintaining a high proportion of HSCs with self-renewal ability. The PDGFR inhibitors discovered by the applicant are significantly more effective than the reported small chemical molecules in expanding LT-HSCs. This is the first time to demonstrate and report that the PDGF/PDGFR signaling pathway plays an important role in the expansion of hematopoietic stem cells and the maintenance of self-renewal ability. The applicant&#39;s research results can realize the in vitro expansion of HSCs while maintaining a high proportion of stemness of cells. On this basis, the clinical application of HSCs transplantation can widely treat a series of hematological diseases.
Conformational isomers of modified versions of α-Synuclein (αSyn), a protein that is associated with Parkinson&#39;s disease, have been designed and produced. These conformational isomers are produced by introducing cysteines into the α-Synuclein and scrambling the disulfide bonds to form stable and immunogenic isomers. These isomers are generically referred to as X-isomers. X-αSyn is an X-isomer of αSyn. X-αSyn is generally more immunogenic than wt-αSyn. Two groups of X-αSyn have been produced. One group is 3-disulfide X-αSyn(3SS) produced by introducing 6 Cys mutations into the αSyn. The second group is 2-disulfide X-αSyn(2SS), produced by introducing 4 Cys mutations into the α-Syn. In each of these two groups of X-αSyn, Cys was introduced not only wt-αSyn, but also in two Parkinson Disease associated αSyn mutants, A30P-αSyn and A53T-αSyn. All six sets of X-αSyn exhibit enhanced aggregation as compared to wt-αSyn, and should therefore more much more immunogenic. It was discovered that refolding the proteins in a CuSO 4  buffer greatly enhanced oxidation and therefore diversity of the refolded proteins. Production of antibodies to X-αSyn is useful because such antibodies should bind to wt-αSyn and thus be useful as a therapeutic or for detection of αSyn in subjects.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means for regulating angiogenesis, i.e., a means for promoting even the angiogenesis of a group of specific subjects, e.g., the aged and the like, which is difficult to promote by conventional methods, and accurately regulating angiogenesis at a predetermined site.  &lt;P&gt;SOLUTION: EC progenitors can be used in a method for regulating angiogenesis, i.e., the method for enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g. anti- or pro-angiogenic agents, respectively, to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a carbon dioxide composition for external use obtaining strong cosmetic and medical effects by solely applying thinly a little amount for a short period of time.  &lt;P&gt;SOLUTION: The carbon dioxide composition for external use in which carbon dioxide is dissolved in a non-bubble state in a viscous material comprising at least water and a thickener is provided. The composition can be simply mass-produced by using an impermeable sealable mixer. Another method for producing the carbon dioxide composition for external use is to produce carbon dioxide by fermentation bacteria in a sealable container, thereby not only production of the carbon dioxide composition for external use and filing to the sealable container are carried out only once, but secondary metabolites additively or synergistically acting to the cosmetic and medical effects of carbon dioxide are generated by the bacterial strain and the carbon dioxide composition for external use having higher additional values is obtained. Another carbon dioxide composition for external use includes at least the fermentation bacteria, metabolites of the same, a thickener, water and carbon dioxide. The strong cosmetic and medical effects can be simply obtained by using a little amount of the carbon dioxide composition for external use.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Histologic classification of pathology specimens through machine learning is a nascent field which offers tremendous potential to improve cancer medicine. Its utility has been limited, in part because of differences in tissue preparation and the relative paucity of well-annotated images. We introduce tissue recognition, an unsupervised learning problem analogous to human face recognition, in which the goal is to identify individual tumors using a learned set of histologic features. This feature set is the “tissue fingerprint.” Because only specimen identities are matched to fingerprints, constructing an algorithm for producing them is a self-learning task that does not need image metadata annotations. Here, we provide an algorithm for self-learning tissue fingerprints, that, in conjunction with color normalization, can match hematoxylin and eosin stained tissues to one of 104 patients with 93% accuracy. We applied this identification network&#39;s internal representation as a tissue fingerprint for use in predicting the molecular status of an individual tumor (breast cancer clinical estrogen receptor (ER) status). We describe a fingerprint-based classifier that predicts ER status from whole-slides with high accuracy (AUROC=0.90), and is an improvement over traditional transfer learning approaches. The use of tissue fingerprinting for digital pathology as a concise but meaningful histopathologic image representation enables a new range of machine learning algorithms leading to increased information for clinical decision making in patient management.
The present application provides acetone-containing and acetone-free solvent compositions. The compositions may be non-aerosolizable. The compositions may also contain a propellant and be aerosolizable. The aerosolizable compositions may be stored and used in an aerosol container, which can produce a relatively coarse spray containing the aerosolizable composition. In one aspect, the compositions of the present disclosure are cosmetic compositions, e.g., nail polish remover compositions. Also provided are the methods for removing nail polish from a person&#39;s nail using the aerosolizable and non-aerosolizable solvent compositions.
The invention belongs to the fields of treatment of skin scalds, skin disinfection sterilization, prevention and treatment of vagina inflammatory diseases, sex-health products and contraceptives, and is characterized is in that: oil fried pepper is used, or a pepper extract product is added into oil, and then benzalkonium chloride or benzalkonium bromide and metronidazole and other corresponding materials are added. The raw materials have synergistic effects. The purpose of relieving pain without blisters or scars can be achieved within about two or three minutes by application of the product on a scald part. 99.9% of escherichia coli, staphylococcus aureus and pseudomonas aeruginosa can be killed within about three minutes by application of the product on skin. The product meets national disinfection-relevant drug standers, when a female clitoris or a male balanus is coated with the product, the product can promote the orgasm, and the effective rate is 58%. According to the report, &#34;Viagra&#34; trial efficiency in Chinese is 40-80%, and is 60% in average. The product can be used simultaneously by a woman and a man or by one of the woman and the man, and is more precious. The product simultaneously has the effects of prevention and treatment of the vagina inflammatory diseases, contraception and the like. The raw material cost is low, production process and production equipment are simple and convenient, and the product profit is extremely high. The product has the advantages of small dosage, high safety and no toxic or side effect.
PURPOSE:To obtain a base for solid drug reparation, capable of freely controlling the release of the drug and having both rapid-releasing and slow-releasing activity to a drug, by dissolving a pH-dependent enteric polymer under specific condition in a polyalkylene glycol which is solid at room temperature. CONSTITUTION:The objective base can be produced by dissolving (A) a pH- dependent enteric polymer (e.g. cellulose acetate phthalate) having the following characteristics in (B) a polyalkylene glycol (e.g. polyethylene glycol) which is solid at room temperature, preferably at &lt;=40 deg.C. The enteric polymer is (i) soluble in said polyalkylene glycol, (ii) soluble in water at 5-7pH and (iii) hardly soluble in water compared with said polyalkylene glycol. The dissolution can be carried out either by heating and melting the polyalkylene glycol and dissolving the pH-dependent polymer in the melt, or by dissolving the polymer using a solvent. A drug is added to the base and the mixture is formed in the from of a solid drug, especially a suppository, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition and a method for stimulating or inhibiting the angiogenesis and/or cardiovascularization of mammals including human.  &lt;P&gt;SOLUTION: The pharmaceutical composition is based on polypeptides or antagonists thereto identified for one or more of those uses. Disorders that can be diagnosed, prevented or treated by the composition include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to new polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric molecules comprising the polypeptides fused to heterologous polypeptides, antibodies binding to the polypeptides and a method for producing the polypeptides.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: medicine.SUBSTANCE: biocompatible implant (BI) made of magnetic material in a biocompatible matrix (BM) is placed loosely along a posterior surface of an injured spinal cord of an experimental animal (EA) The EA is immersed periodically into a constant magnetic field. Its magnetic vector is aligned with a craniocaudal direction of spinal tracts. The BM of the BI is animal or herbal gelatine, wherein ferromagnetic magnetite or ferromagnetic ferrite nanoparticles 18-42 wt % with a particle size of 2.0-38 nm and at a magnetic field intensity (N) of 5-10 mT are immobilised as a magnetic material of the BI. The magnetic exposure covering the traumatic spinal injuries involves the combined effect of the magnetic field of the BI and the external rotating magnetic field at a magnetic induction of 0.15-0.35 T. The external magnetic exposure frequency is 1 or 2 times a day; the length is from 2 to 8 minutes per one session; the number of sessions is from 2 to 4. Animal gelatine in the BM of the BI can represent agar-agar, whereas herbal gelatine is pectin. The BM of the BI can additionally contain polyamines contributing to cell growth and proliferation, e.g. spermine or spemidine, in an amount of 1-5 wt %.EFFECT: method enables recovering the spinal cord function sufficiently completely in the distal direction from the injury region, providing the favourable conditions for the adequate neuroglial growth with recipient&#39;s long neuron penetration from the intact proximal portion of the spinal cord into the distal one to ensure its conductive function, reducing the cicatrisation within the spinal injury, and eliminating the cerebral tissue oedema.3 cl, 8 ex
Hemodialysis (HD) is the primary renal replacement therapy for patients with end-stage renal disease. However, residual renal function (RRF) characteristically declines after these individuals start dialysis. This loss of RRF not only impacts the adequacy of dialysis and control of complications but also affects the patient\&amp;#39;s quality of life and survival prospects. Due to a lack of clear understanding regarding the pathophysiology underlying this decline in RRF, no effective strategies exist for its preservation at present. The objective of this study is to explore the changes in renal perfusion during hemodialysis in patients with end-stage renal disease, and provide a new idea for protection of RRF. This study was an observational study, and no interventions were performed.
A method for rejuvenation of the face comprises the clinical examination, the diagnosing and the treatment itself. Once or twice a month, 10 % solution of calcium chloride is applied onto the cleaned skin. Upon drying, the application is repeated 2-3 times. Then the dry skin is treated with the soap by the massaging movements spreading the soap foam along the lines of the massage excluding the skin under the eyes. The &#34;flakes&#34; are removed from the face by the slow soft movements of the fingers. If required, the procedure with the soap is repeated. Following 3-minute rest, the face is washed with the warm water, and the moistening cream is applied. The result of the treatment is finally assessed visually.